<DOC>
	<DOCNO>NCT02267746</DOCNO>
	<brief_summary>The purpose study compare safety therapeutic equivalence generic tazarotene foam 0.1 % reference list Fabior™ ( tazarotene foam , 0.1 % ) treatment acne vulgaris .</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Therapeutic Equivalence Tazarotene Foam 0.1 % Subjects With Acne Vulgaris</brief_title>
	<detailed_description>Although topical retinoids individually use successfully treat acne vulgaris , Fabior™ ( Tazarotene ) Foam , 0.1 % safe effective topical therapy use treatment acne vulgaris . Actavis develop generic formulation Tazarotene Foam , 0.1 % , current study design evaluate safety efficacy formulation .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Healthy male nonpregnant female age ≥ 12 ≤ 40 year clinical diagnosis acne vulgaris . Informed Consent/Assent : Subjects age 12 17 year inclusive must provide IRB approve write assent ; write assent must accompany IRB approve write informed consent Subject 's legally acceptable representative ( i.e. , parent guardian ) . In addition , Subjects legally acceptable representative ( i.e. , parent guardian ) must sign HIPAA authorization . Subjects must minimum ≥ 30 noninflammatory lesion ( i.e. , open close comedo ) AND ≥ 25 inflammatory lesion ( i.e. , papule pustule ) AND cystic lesion 1 facial nodular lesion ( less equal 5 mm ) face . For purpose study treatment evaluation , lesion limit facial treatment area exclude eye , lip , angle nose ( i.e . line around nostril nostril ) mucus membrane . Subjects may acne lesion area body also exclude count , treatment , Investigator 's Global Assessment ( IGA ) evaluation ( e.g. , back , chest arm ) . Subjects must severity grade 3 , 4 per Investigator 's Global Assessment ( IGA ) ( Section 6.2 ) . Subjects must willing refrain use topical acne medication antibiotics 12week treatment period acne vulgaris , Investigational Product . Female Subjects childbearing potential ( exclude woman surgically sterilize postmenopausal least 1 year ) , must negative urine pregnancy test ( sensitivity least 50mIU/ml hCG ) within 2 week prior baseline . Female Subjects childbearing potential ( exclude woman surgically sterilize postmenopausal least 1 year ) , must willing use acceptable form birth control day first dose administration.. For purpose study follow consider acceptable method birth control : oral injectable contraceptive , contraceptive patch , DepoProvera® ( stabilize least 3 month ) ; NuvaRing® ( vaginal contraceptive ) ; Implanon™ ( contraceptive implant ) double barrier method ( e.g . condom spermicide ) ; IUD , abstinence 2nd acceptable method birth control Subject become sexually active . A sterile sexual partner NOT consider adequate form birth control . All male Subjects must agree use accept method birth control partner , day first dose administration . Abstinence acceptable method birth control male . Subjects must willing able understand comply requirement protocol , include attendance require study visit . Subjects use makeup must use brands/types makeup minimum period 14 day prior study entry must agree change makeup brand/type frequency use throughout study . Female Subjects pregnant , nurse plan become pregnant study participation . Subjects history hypersensitivity allergy tazarotene excipients , and/or study medication ingredient . Subjects presence skin condition would interfere diagnosis assessment acne vulgaris . Such condition include , limited following : auto immune disease , rosacea ; seborrheic dermatitis ; perioral dermatitis ; corticosteroidinduced acne ; carcinoid syndrome ; mastocytosis ; acneform eruption cause makeup , medication , facial psoriasis facial eczema , squamous cell carcinoma , steroid folliculitis , bacterial folliculitis ) . Subjects acne congoblata , acne fulminans , secondary acne ( e.g. , chloracne drug induce acne ) exclude participation . Subjects excessive facial hair ( e.g . beard , sideburn , moustache , etc . ) would interfere diagnosis assessment acne vulgaris . Subjects use follow within 6 month prior baseline use study : 1. oral retinoids ( e.g . Accutane® ) 2. therapeutic vitamin A supplement great 10,000 units/day ( multivitamin allow ) . Subjects use estrogens oral contraceptive le 3 month prior baseline ; use therapy must remain constant throughout study . Subjects use androgen receptor blocker ( spironolactone flutamide ) exclude study participation . Subjects cosmetic procedure ( e.g. , facial , wax depilation ) may affect efficacy safety profile investigational product within 14 day prior study entry . Cosmetic procedure facial prohibit throughout study . Subjects receive radiation therapy and/or antineoplastic agent within 90 day prior baseline . Subjects laser therapy , electrodessication phototherapy ( e.g. , ClearLight® ) facial area within 180 day prior study entry . Subjects use follow procedure face within 1 month prior baseline study : 1. cryodestruction chemodestruction , 2. dermabrasion , 3. photodynamic therapy , 4. acne surgery , 5. intralesional steroid , 6 . Xray therapy . Subjects use follow treatment within 1 month prior baseline study : 1. systemic corticosteroid ( include intranasal inhaled corticosteroid ) 2. systemic antibiotic , 3. systemic treatment acne vulgaris ( oral retinoids need 6month washout ) , 4. systemic antiinflammatory agent . Subjects use follow treatment within 14 day prior baseline study : 1. topical steroid , 2. topical retinoids include overthecounter preparation , 3. αhydroxy/glycolic acid 4. topical antiinflammatory agent , 5. topical antibiotic . Subjects start hormonal therapy change dosage hormonal therapy within 3 month prior baseline exclude study participation . The dosage frequency use hormonal therapy start great 3 month prior baseline must remain unchanged throughout study ( Visit 1 Visit 4 ) . Hormonal treatment include , limited , estrogenic progestational agent birth control pill . Subjects unstable medical disorder clinically significant lifethreatening disease exclude study participation . Subjects current facial sunburn baseline subject excessive use tan booth , sunbathe , excessive exposure sun study . Subjects engage activity involve excessive prolonged exposure sunlight weather extreme , wind cold . Subjects ongoing malignancy require systemic treatment exclude study participation . In addition , Subjects malignancy skin facial area exclude . Subjects consume excessive amount alcohol ( great two drink per day ) use drug abuse ( include , limited cannabinoids , cocaine barbiturate ) . Subjects general anesthesia reason subject receive neuromuscular block agent within 14 day prior study entry exclude study participation . Subjects participate investigational drug study ( i.e. , Subjects treat Investigational Drug ) within 30 day prior baseline exclude study participation . Subjects participate nontreatment study observational study registry study consider inclusion . Subjects previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>